US 12,029,712 B2
Deuterated analogs of D-serine and uses thereof
Dario Doller, Sparta, NJ (US); Christopher L. Brummel, Marlborough, MA (US); Julie F. Liu, Lexington, MA (US); and Roger D. Tung, Lexington, MA (US)
Assigned to Sun Pharmaceutical Industries, Inc., Princeton, NJ (US)
Filed by Sun Pharmaceutical Industries, Inc., Princeton, NJ (US)
Filed on May 27, 2020, as Appl. No. 16/884,652.
Application 16/884,652 is a continuation of application No. 16/459,916, filed on Jul. 2, 2019, granted, now 10,668,036.
Application 16/459,916 is a continuation of application No. PCT/US2018/062263, filed on Nov. 21, 2018.
Claims priority of provisional application 62/755,157, filed on Nov. 2, 2018.
Claims priority of provisional application 62/636,427, filed on Feb. 28, 2018.
Claims priority of provisional application 62/636,081, filed on Feb. 27, 2018.
Claims priority of provisional application 62/590,109, filed on Nov. 22, 2017.
Prior Publication US 2020/0390732 A1, Dec. 17, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/197 (2006.01); A61K 9/00 (2006.01); A61K 31/198 (2006.01); A61K 45/06 (2006.01); A61P 25/18 (2006.01)
CPC A61K 31/197 (2013.01) [A61K 9/0053 (2013.01); A61K 31/198 (2013.01); A61K 45/06 (2013.01); A61P 25/18 (2018.01)] 25 Claims
 
1. A method of treating epilepsy, NMDAR encephalitis, Parkinson's disease, cognitive deficits in Parkinson's disease, Alzheimer's disease, mild cognitive impairment, amyotrophic lateral sclerosis (ALS), Huntington's disease, bipolar disorder, bipolar mania, bipolar depression, treatment-refractory depression, cognitive deficits in depression, major depressive disorder, generalized anxiety disorder, major depressive disorder with mixed features, and cognition deficits associated with Huntington's disease, subjective cognitive decline, traumatic brain injury, or Lewy Body Dementia, the method comprising administering to a subject in need thereof an effective amount of
Compound 100:

OG Complex Work Unit Chemistry
wherein each position designated specifically as deuterium has at least 90% incorporation of deuterium; and wherein the compound is at least about 90% stereomerically pure;
or a pharmaceutically acceptable salt thereof.